BullStreet.com.au -ASX News & Insights’ Post

Kairos Pharma Ltd. (NYSE: KAPA) today announced its approval to dual list its shares on Upstream. Trading will become available on Upstream November 26th at 10:00 am ET under the ticker symbol ‘KAPA’. The dual listing on Upstream is designed to provide Kairos Pharma the opportunity to access a global investor base outside the U.S., unlocking liquidity and enhancing price discovery while globalizing the opportunity to invest in Kairos Pharma. Dr. John Yu, CEO of Kairos Pharma, commented, “Building shareholder value is an ongoing goal of Kairos. We believe a dual listing on Upstream’s next generation market greatly supports this goal as we continue to expand our lead drug ENV105 to several widespread cancers and to advance our therapeutics through clinical testing and commercialization.” Press Release: https://lnkd.in/gsZ8s2Jm -- Disclaimers: U.S. or Canadian persons may not deposit, buy, or sell securities on Upstream: https://lnkd.in/ehaxqkXV

Forte Biosciences (NASDAQ: $FBRX)Secures $53 Million to Fast-Track Breakthrough Autoimmune Therapy; Stock Soars 137% Forte Biosciences, Inc. (NASDAQ: FBRX), a clinical-stage biopharmaceutical company specializing in autoimmune diseases, has raised $53 million in an oversubscribed private placement. The funds will support the continued development of FB102, Forte's leading therapeutic candidate targeting a broad range of autoimmune and related conditions. The financing drew participation from top-tier healthcare institutional investors, including OrbiMed, Janus Henderson Investors, and Tybourne Capital Management. This significant capital injection positions Forte to advance FB102 into additional clinical trials over the next year, with celiac disease trials currently underway and topline data expected in Q2 2025. Forte's CEO, Paul Wagner, Ph.D., highlighted the transformative impact of the financing, emphasizing its importance in achieving critical clinical milestones in 2025. The company plans to share further details at its upcoming R&D Day on December 3rd. TD Cowen led the placement, with support from Guggenheim Securities and co-placement managers Chardan, Rodman & Renshaw, and Brookline Capital Markets. FB102, an anti-CD122 monoclonal antibody, is central to Forte’s efforts to address unmet needs in autoimmune diseases, with promising potential across multiple indications. #ForteBiosciences #AutoimmuneTherapy #AutoimmuneDisease #stockstowatch #stocksinnews #investors #daytrader #PrismMarketView #PrismMediaWire #PrismDigitalMedia #ForteBiosciences https://lnkd.in/eqJ-GFuk

𝐒𝐜𝐢𝐧𝐚𝐢 𝐈𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐋𝐭𝐝. 𝐒𝐞𝐜𝐮𝐫𝐞𝐬 $𝟐 𝐌𝐢𝐥𝐥𝐢𝐨𝐧 𝐏𝐫𝐢𝐯𝐚𝐭𝐞 𝐄𝐪𝐮𝐢𝐭𝐲 𝐂𝐨𝐦𝐦𝐢𝐭𝐦𝐞𝐧𝐭 𝐟𝐫𝐨𝐦 𝐋𝐚𝐫𝐠𝐞𝐬𝐭 𝐒𝐡𝐚𝐫𝐞𝐡𝐨𝐥𝐝𝐞𝐫: 𝐀 𝐕𝐨𝐭𝐞 𝐨𝐟 𝐂𝐨𝐧𝐟𝐢𝐝𝐞𝐧𝐜𝐞 𝐢𝐧 𝐎𝐮𝐫 𝐕𝐢𝐬𝐢𝐨𝐧 𝐚𝐧𝐝 𝐅𝐮𝐭𝐮𝐫𝐞 We're excited to announce that Scinai has entered into a $2 million private equity commitment agreement with our largest existing shareholder, RK Stone Miami LLC. This significant investment underscores the confidence our shareholders have in our company’s direction and long-term potential. 𝑇ℎ𝑖𝑠 𝑐𝑎𝑝𝑖𝑡𝑎𝑙 𝑤𝑖𝑙𝑙 𝑏𝑒 𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑖𝑐𝑎𝑙𝑙𝑦 𝑖𝑛𝑣𝑒𝑠𝑡𝑒𝑑 𝑖𝑛 𝑎𝑑𝑣𝑎𝑛𝑐𝑖𝑛𝑔 𝑜𝑢𝑟 𝑟𝑒𝑠𝑒𝑎𝑟𝑐ℎ 𝑎𝑛𝑑 𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑚𝑒𝑛𝑡 𝑒𝑓𝑓𝑜𝑟𝑡𝑠 𝑜𝑓 𝑜𝑢𝑟 𝑎𝑛𝑡𝑖-𝐼𝐿-17 𝑛𝑎𝑛𝑜𝐴𝑏 𝑓𝑜𝑟 𝑡ℎ𝑒 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑜𝑓 𝑝𝑙𝑎𝑞𝑢𝑒 𝑝𝑠𝑜𝑟𝑖𝑎𝑠𝑖𝑠, 𝑎𝑠 𝑤𝑒𝑙𝑙 𝑎𝑠 𝑎𝑐𝑐𝑒𝑙𝑒𝑟𝑎𝑡𝑖𝑛𝑔 𝑡ℎ𝑒 𝑐𝑜𝑚𝑚𝑒𝑟𝑐𝑖𝑎𝑙 𝑔𝑟𝑜𝑤𝑡ℎ 𝑜𝑓 𝑜𝑢𝑟 𝐶𝐷𝑀𝑂 𝑏𝑢𝑠𝑖𝑛𝑒𝑠𝑠 𝑢𝑛𝑖𝑡. 𝑇ℎ𝑒 𝑎𝑔𝑟𝑒𝑒𝑚𝑒𝑛𝑡, 𝑠𝑡𝑟𝑢𝑐𝑡𝑢𝑟𝑒𝑑 𝑎𝑠 𝑎 𝑙𝑜𝑛𝑔-𝑡𝑒𝑟𝑚 𝑐𝑜𝑚𝑚𝑖𝑡𝑚𝑒𝑛𝑡, 𝑟𝑒𝑓𝑙𝑒𝑐𝑡𝑠 𝑎 𝑠ℎ𝑎𝑟𝑒𝑑 𝑏𝑒𝑙𝑖𝑒𝑓 𝑖𝑛 𝑆𝑐𝑖𝑛𝑎𝑖’𝑠 𝑚𝑖𝑠𝑠𝑖𝑜𝑛 𝑡𝑜 𝑖𝑛𝑛𝑜𝑣𝑎𝑡𝑒 𝑎𝑛𝑑 𝑔𝑟𝑜𝑤 𝑖𝑛 𝑡ℎ𝑒 𝑏𝑖𝑜𝑝ℎ𝑎𝑟𝑚𝑎𝑐𝑒𝑢𝑡𝑖𝑐𝑎𝑙 𝑠𝑝𝑎𝑐𝑒. We’re proud to have the support of such a strong partner as we continue to push the boundaries of inflammation and immunology treatments. Together, we’re building a brighter future for our company and the patients we serve. #Scinai #Investment #Growth #Biotech #CDMO #ResearchAndDevelopment #Innovation https://lnkd.in/dWD6r_Us Amir Reichman

Clene Inc. (NASDAQ: CLNN), a biopharmaceutical company focused on improving mitochondrial health, recently presented its achievements at the H.C. Wainwright 26th Annual Global Investment Conference. The company highlighted its lead drug candidate, CNM-Au8, which has shown promise in restoring and protecting neurological function for neurodegenerative conditions. Clene Nanomedicine, Inc. is seeking FDA approval to file a new drug application for CNM-Au8, utilizing the accelerated approval pathway for the treatment of amyotrophic lateral sclerosis (ALS). The company's management presented recent results and plans for CNM-Au8 during the conference, held virtually from Sept. 9-11. 'We are excited about the potential of CNM-Au8 to provide new hope for patients with neurodegenerative diseases,' said Rob Etherington, President and CEO of Clene. 'The data so far is encouraging, and we look forward to advancing this promising therapeutic candidate.' #neurodegenerative #als #ms #biotech IBN (InvestorBrandNetwork)

The Affordable Edge: Transforming the Specialty Pharmaceuticals SectorIn the speciality pharmaceuticals sector, striking a balance between profitability and drug affordability is crucial. Conditions like cancer and Alzheimer’s necessitate advanced, targeted therapies, which are initially expensive due to their extensive research and development phases. https://lnkd.in/gmU6cnnA #onlinepharmacy #mrmed #onlinemedicineshop #superspeciltypharmacy #ordermedicineonline

Reviva Pharmaceuticals Announces $1.2 Million Public Offering to Fuel R&D Growth 💡 Reviva Pharmaceuticals Holdings, Inc. has priced an underwritten public offering, aiming to raise funds for advancing its CNS, inflammatory, and cardiometabolic disease therapies: 📈 12 million shares of common stock, priced at $1.50 per share 🔑 Includes Series A warrants for 6 million shares and Series B warrants for 12 million shares 💰 Funds will support research and development and corporate initiatives Reviva plans to use the proceeds to advance its clinical pipeline, focusing on treatments for central nervous system disorders, inflammatory diseases, and cardiometabolic conditions. The company aims to accelerate its ongoing research efforts, including late-stage clinical trials, and strengthen its infrastructure to support future growth. 📊 Read more at 👉🏻 https://shorturl.at/MbKLy #RevivaPharmaceuticals #PublicOffering #PharmaceuticalInnovation #CNS #Cardiometabolic #Warrants #R&D #Biotech #Investment

The biotech sector is witnessing a resurgence, fueled by robust fundraising efforts and an uptick in IPOs. This turnaround is exemplified by companies like Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) and Kiniksa Pharmaceuticals (NASDAQ:KNSA), which are developing promising therapies for rare diseases. 'Cardiol Therapeutics' lead product, CardiolRx™, secured Orphan Drug Designation from the FDA for treating pericarditis, a rare condition affecting fewer than 200,000 people in the U.S. This designation offers regulatory and financial benefits, positioning the company for potential success. Analysts are optimistic about the upcoming Phase 2 trial data, anticipated in June, which could unlock significant shareholder value. 'Kiniksa Pharmaceuticals' ARCALYST® is the first and only FDA-approved therapy for recurrent pericarditis. With sales reaching $233.2 million in 2023, the company illustrates the massive revenue potential for effective treatments in this space. Kiniksa anticipates bringing in between $370 million and $390 million in 2024, representing substantial year-over-year growth. @cardiolthera @kiniksapharm #biotechnology #orphandrugs #pericarditis #fda #clinicaltrials #investmentopportunities #rarediseases

Pharma service providers, did you know that in the last 24 hours, over 35 pharma and biotech companies in North America have announced upcoming Phase 1, 2, and 3 studies? 🚀 Take NeuroBo Pharmaceuticals as an example; with a lean team of 10 and over $85M in funding this year, they are advancing towards a Phase 2 study targeting cardiomyopathy associated with DMD and cystic fibrosis. Stay ahead and turn these actionable insights into opportunities! DM or email me at amarpreet.singh@zymewire.com to explore how Zymewire can help you stay proactive and capture these insights.

AC Immune is honored to be among the finalists for Deal of the Year at the prestigious Scrip Awards 2024 for our exclusive, worldwide option and license agreement with Takeda, covering ACI-24.060 and other active immunotherapies targeting amyloid beta. Our collaboration with Takeda is forging a new path to address significant unmet needs in neurodegenerative diseases and advance innovative solutions for Alzheimer’s. The Scrip Deal of the Year Award recognizes agreements that deliver outstanding value, including accelerating innovative therapies to market, replenishing pharmaceutical pipelines, and generating significant benefits for partners and stakeholders. We congratulate the other finalists: AstraZeneca Fusion Pharmaceuticals Gracell Biotechnologies Daiichi Sankyo US Merck Group Intas Pharmaceuticals Henlius Johnson & Johnson Protagonist Therapeutics Sanofi and Teva Pharmaceuticals. #ScripAwards2024 #DealOfTheYear #Alzheimers #Innovation #Partnership #PrecisionMedicine